Toll Free: 1-888-928-9744

Anaplastic Thyroid Cancer - Pipeline Review, H2 2015

Published: Jul, 2015 | Pages: 81 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Anaplastic Thyroid Cancer - Pipeline Review, H2 2015

Summary

Global Markets Direct's, 'Anaplastic Thyroid Cancer - Pipeline Review, H2 2015', provides an overview of the Anaplastic Thyroid Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Anaplastic Thyroid Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Anaplastic Thyroid Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Anaplastic Thyroid Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Anaplastic Thyroid Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Anaplastic Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Anaplastic Thyroid Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Anaplastic Thyroid Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Anaplastic Thyroid Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 Anaplastic Thyroid Cancer Overview 7 Therapeutics Development 8 Pipeline Products for Anaplastic Thyroid Cancer - Overview 8 Pipeline Products for Anaplastic Thyroid Cancer - Comparative Analysis 9 Anaplastic Thyroid Cancer - Therapeutics under Development by Companies 10 Anaplastic Thyroid Cancer - Therapeutics under Investigation by Universities/Institutes 11 Anaplastic Thyroid Cancer - Pipeline Products Glance 12 Clinical Stage Products 12 Early Stage Products 13 Anaplastic Thyroid Cancer - Products under Development by Companies 14 Anaplastic Thyroid Cancer - Products under Investigation by Universities/Institutes 15 Anaplastic Thyroid Cancer - Companies Involved in Therapeutics Development 16 Daiichi Sankyo Company, Limited 16 Exelixis, Inc. 17 Genelux Corporation 18 GlaxoSmithKline Plc 19 Immune Pharmaceuticals Inc. 20 Millennium Pharmaceuticals, Inc. 21 Novartis AG 22 Plexxikon Inc. 23 Anaplastic Thyroid Cancer - Therapeutics Assessment 24 Assessment by Monotherapy Products 24 Assessment by Combination Products 25 Assessment by Target 26 Assessment by Mechanism of Action 28 Assessment by Route of Administration 30 Assessment by Molecule Type 32 Drug Profiles 34 (dabrafenib mesylate + trametinib dimethyl sulfoxide) - Drug Profile 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 cabozantinib s-malate - Drug Profile 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ceritinib - Drug Profile 39 Product Description 39 Mechanism of Action 39 R&D Progress 39 CLM-3 - Drug Profile 42 Product Description 42 Mechanism of Action 42 R&D Progress 42 CLM-94 - Drug Profile 43 Product Description 43 Mechanism of Action 43 R&D Progress 43 crolibulin - Drug Profile 44 Product Description 44 Mechanism of Action 44 R&D Progress 44 efatutazone - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 GLONC-2 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 PLX-3397 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 PLX-8394 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 sapanisertib - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 Anaplastic Thyroid Cancer - Recent Pipeline Updates 55 Anaplastic Thyroid Cancer - Dormant Projects 78 Anaplastic Thyroid Cancer - Product Development Milestones 79 Featured News & Press Releases 79 Apr 18, 2013: Combination Therapy Shows Promise Against Anaplastic Thyroid Cancer, Study Finds 79 Appendix 80 Methodology 80 Coverage 80 Secondary Research 80 Primary Research 80 Expert Panel Validation 80 Contact Us 80 Disclaimer 81
List of Tables
Number of Products under Development for Anaplastic Thyroid Cancer, H2 2015 8 Number of Products under Development for Anaplastic Thyroid Cancer - Comparative Analysis, H2 2015 9 Number of Products under Development by Companies, H2 2015 10 Number of Products under Investigation by Universities/Institutes, H2 2015 11 Comparative Analysis by Clinical Stage Development, H2 2015 12 Comparative Analysis by Early Stage Development, H2 2015 13 Products under Development by Companies, H2 2015 14 Products under Investigation by Universities/Institutes, H2 2015 15 Anaplastic Thyroid Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2015 16 Anaplastic Thyroid Cancer - Pipeline by Exelixis, Inc., H2 2015 17 Anaplastic Thyroid Cancer - Pipeline by Genelux Corporation, H2 2015 18 Anaplastic Thyroid Cancer - Pipeline by GlaxoSmithKline Plc, H2 2015 19 Anaplastic Thyroid Cancer - Pipeline by Immune Pharmaceuticals Inc., H2 2015 20 Anaplastic Thyroid Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2015 21 Anaplastic Thyroid Cancer - Pipeline by Novartis AG, H2 2015 22 Anaplastic Thyroid Cancer - Pipeline by Plexxikon Inc., H2 2015 23 Assessment by Monotherapy Products, H2 2015 24 Assessment by Combination Products, H2 2015 25 Number of Products by Stage and Target, H2 2015 27 Number of Products by Stage and Mechanism of Action, H2 2015 29 Number of Products by Stage and Route of Administration, H2 2015 31 Number of Products by Stage and Molecule Type, H2 2015 33 Anaplastic Thyroid Cancer Therapeutics - Recent Pipeline Updates, H2 2015 55 Anaplastic Thyroid Cancer - Dormant Projects, H2 2015 78



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify